Still some unanswered questions on their study from January article as shown below:

“…………..
As such, detail on several safety measures investors were looking for, namely unwanted effects on cartilage, bone and heart rate, were not provided. These are relevant given resmetirom’s activity as a thyroid hormone receptor beta agonist, and all management would do is cite earlier reassuring data.
And the other part of the FDA-approvable Nash endpoint is no fibrosis worsening, and here Madrigal again left investors unsatisfied. A key metric would be the Fibroscan data used to enrol patients into Maestro-NAFLD-1, and how this finding changed over 52 weeks, but the company said these data had not yet been analysed.
………….”

https://www.evaluate.com/vantage/articles/new...focus-nash